Results 171 to 180 of about 39,319 (333)

CXCR4 WHIM‐like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88^L265P‐directed survival signalling in Waldenström macroglobulinaemia cells [PDF]

, 2014
Yang Cao, Zachary R. Hunter, Xia Liu, Lian Xu, Guang Yang, Jie Chen, Nickolas Tsakmaklis, Sandra Kanan, Jorge J. Castillo, Steven P. Treon   +9 more
openalex   +1 more source

Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era

Internal Medicine Journal, EarlyView.
Abstract Background Allogeneic haemopoietic stem cell transplantation (HSCT) is an effective therapy with curative potential for patients with high‐risk or relapsed/refractory chronic lymphocytic leukaemia (CLL). There are limited data on the use and outcomes of HSCT in the modern era of CLL treatment.
Luani Barge, Steven Tran, Glen Kennedy, David Ritchie, David Gottlieb, Sam Milliken, Andrew Spencer, Duncan Purtill, Travis Perera, Richard Doocey, Stephen Larsen, Andrew Butler, Peter Bardy, Matthew Greenwood, Simon Durrant, Cameron Curley, Caroline Stewart, Constantine Tam, Shalini Balendran, Pietro R. Di Ciaccio, Sushrut Patil, Min‐Hi Han, Nada Hamad   +22 more
wiley   +1 more source

The Ibr‐7 derivative of ibrutinib exhibits enhanced cytotoxicity against non‐small cell lung cancer cells via targeting of mTORC1/S6 signaling

Molecular Oncology, 2019
Ibrutinib is a small molecule drug that targets Bruton's tyrosine kinase in B‐cell malignancies and is highly efficient at killing mantle cell lymphoma and chronic lymphocytic leukemia. However, the anti‐cancer activity of ibrutinib against solid tumors,
Bo Zhang, Linling Wang, Qi Zhang, Youyou Yan, Hong Jiang, Runlei Hu, Xinglu Zhou, Xingguo Liu, Jianguo Feng, Nengming Lin   +9 more
doaj   +1 more source

Prolonged and tunable residence time using reversible covalent kinase inhibitors. [PDF]

, 2015
Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.
Angelina Bisconte, Dane E. Karr, Danny Tam, David Finkle, David G. Loughhead, David M. Goldstein, Erik Verner, J. Hill, J. Michael Bradshaw, Jack Taunton, Jens Oliver Funk, Jesse M. Mcfarl, Jin Shu, Ken A. Brameld, Mary E, Philip A. Nunn, Principia Biopharma, Sergei Romanov, Timothy D. Owens, Tony Ton, Vaishali Patel, Vernon T. Phan, Ville O. Paavilainen, Xiaoyan Li   +23 more
core  

The Dental Status of Patients Taking Common Biologic Agents: A Single‐Center Cross‐Sectional Study

Oral Diseases, EarlyView.
ABSTRACT Objectives Despite expanding use and medical applications, little is known about the impact of biologic agents (BAs) on dental treatment. The aim of this study was to investigate the dental status of patients on common classes of BAs to understand treatment needs and use in this population.
Shivani Shah, Nila Veerabagu, Nana A. A. Essel, Neda Mahjour, Katherine France   +4 more
wiley   +1 more source

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib [PDF]

, 2014
Daphne Guinn, A. S. Ruppert, Kami J. Maddocks, Samantha Jaglowski, Anderley Gordon, Thomas S. Lin, Richard A. Larson, Guido Marcucci, E Hertlein, Jennifer A. Woyach, Amy J. Johnson, John C. Byrd   +11 more
openalex   +1 more source

Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review

European Journal of Haematology, Volume 115, Issue 2, Page 104-116, August 2025.
ABSTRACT Objectives The objective of this systematic literature review (SLR) combined with expert clinical review was to identify and rank prognostic factors and effect measure modifiers (EMMs) systematically and comprehensively in patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who initiate treatment after ≥ 2 prior ...
Bastian von Tresckow, Pau Abrisqueta, Irene Zamanillo, Ángel Serna Pareja, Yuting Kuang, Jennifer Uyei, Mohsin Shah, Laura Walsh, Eileen Thorley, Krystal Cantos, Emaan Rashidi, Christian Hampp, Jessica J. Jalbert, Alexi N. Archambault, Yingxin Xu, Shivani Aggarwal, Srikanth Ambati, Hesham Mohamed, Qiufei Ma, Ana Jiménez‐Ubieto   +19 more
wiley   +1 more source

Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignancies

British Journal of Clinical Pharmacology, Volume 91, Issue 7, Page 2008-2019, July 2025.
Abstract Aims The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese patients with B‐cell malignancies.
Tingting Yao, Junjie Ding, Shringi Sharma, Yunfei Li, Qianwei Xu, Peiming Ma   +5 more
wiley   +1 more source

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK [PDF]

, 2015
Idit Sagiv-Barfi, Holbrook E. Kohrt, Debra K. Czerwinski, Patrick P. Ng, Betty Chang, Ronald Levy   +5 more
openalex   +1 more source

Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis

Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 95-105, July 2025.
After a medicine has been tested in pivotal trials, regulators, health technology assessment (HTA) organizations, and professional societies make decisions about the patients best served by the medicine. This study assesses how the patient populations for oncology medicines (2010–2023) are defined (1) at trial, (2) regulatory submission, (3) upon ...
Milou A. Hogervorst, Rick A. Vreman, Theresa A. Oduol, Aukje K. Mantel‐Teeuwisse, Wim G. Goettsch, Aaron S. Kesselheim   +5 more
wiley   +1 more source